Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AL-15469A/AL-38905; AL-15469A/AL-38905 ophthalmic formulation - Alcon Research; MoxiDex Otic; VIGADEXA

Latest Information Update: 15 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alcon
  • Class Anti-inflammatories; Aza compounds; Fluorinated steroids; Pregnadienetriols; Quinolines
  • Mechanism of Action DNA gyrase inhibitors; Glucocorticoid receptor agonists; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ocular inflammation; Ophthalmic infections
  • Discontinued Corneal disorders; Otitis externa; Otitis media

Most Recent Events

  • 09 Apr 2019 Novartis completed the spin-off of Alcon
  • 05 Apr 2018 Novartis Pharmaceuticals in collaboration with Alcon Research plans a phase II trial for Otitis Externa (In children, In adolescents, In adults, In the elderly) in the US (EudraCT2018-000641-39)
  • 24 Mar 2014 Alcon withdraws a phase III trial for Ocular inflammation and infection (prevention) in Brazil prior to enrolment (NCT01515826) (Ophthalmic, gel)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top